Bristol-Myers Squibb Company

79.98+1.02+1.29%Vol 10.45M1Y Perf 18.31%
Jun 27th, 2022 16:00 DELAYED
BID79.88 ASK80.50
Open79.23 Previous Close78.96
Pre-Market- After-Market79.67
 - -  -0.31 -0.39%
Target Price
78.18 
Analyst Rating
Moderate Buy 2.15
Potential %
-2.25 
Finscreener Ranking
     40.02
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     44.76
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     49.91
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★+     42.21
Price Range Ratio 52W %
103.80 
Earnings Rating
Sell
Market Cap170.28B 
Earnings Date
27th Jul 2022
Alpha0.01 Standard Deviation0.06
Beta0.49 

Today's Price Range

79.1080.59

52W Range

53.2279.00

5 Year PE Ratio Range

-13.30116.80

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
4.59%
1 Month
5.04%
3 Months
9.40%
6 Months
28.28%
1 Year
18.31%
3 Years
76.36%
5 Years
43.15%
10 Years
150.79%

TickerPriceChg.Chg.%
BMY79.981.02001.29
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
1.20
1.30
0.55
1.46
6.60
Leverage Ratio 3.10
ProfitabilityValueIndustryS&P 500US Markets
79.30
18.20
40.80
13.90
13.35
RevenueValueIndustryS&P 500US Markets
46.96B
22.06
25.79
20.30
DividendsValueIndustryS&P 500US Markets
2.93
2.16
10.59
11.43
Payout ratio273.00
Earnings HistoryEstimateReportedSurprise %
Q01 20221.921.962.08
Q04 20211.831.830.00
Q03 20211.912.004.71
Q02 20211.881.932.66
Q01 20211.801.74-3.33
Q04 20201.371.466.57
Q03 20201.491.639.40
Q02 20201.461.6311.64
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.90-5.47Negative
9/2022 QR1.95-2.01Negative
12/2022 FY7.56-3.08Negative
12/2023 FY8.15-1.69Negative
Next Report Date27th Jul 2022
Estimated EPS Next Report1.90
Estimates Count7
EPS Growth Next 5 Years %6.20
Volume Overview
Volume10.45M
Shares Outstanding2.13M
Shares Float2.13B
Trades Count86.26K
Dollar Volume834.61M
Avg. Volume13.33M
Avg. Weekly Volume12.25M
Avg. Monthly Volume13.65M
Avg. Quarterly Volume14.08M

Bristol-Myers Squibb Company (NYSE: BMY) stock closed at 79.98 per share at the end of the most recent trading day (a 1.29% change compared to the prior day closing price) with a volume of 10.45M shares and market capitalization of 170.28B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30250 people. Bristol-Myers Squibb Company CEO is Giovanni Caforio.

The one-year performance of Bristol-Myers Squibb Company stock is 18.31%, while year-to-date (YTD) performance is 28.28%. BMY stock has a five-year performance of 43.15%. Its 52-week range is between 53.22 and 79, which gives BMY stock a 52-week price range ratio of 103.80%

Bristol-Myers Squibb Company currently has a PE ratio of 26.20, a price-to-book (PB) ratio of 4.97, a price-to-sale (PS) ratio of 3.34, a price to cashflow ratio of 10.10, a PEG ratio of 2.32, a ROA of 5.80%, a ROC of 9.09% and a ROE of 18.07%. The company’s profit margin is 13.35%, its EBITDA margin is 40.80%, and its revenue ttm is $46.96 Billion , which makes it $22.06 revenue per share.

Of the last four earnings reports from Bristol-Myers Squibb Company, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.90 for the next earnings report. Bristol-Myers Squibb Company’s next earnings report date is 27th Jul 2022.

The consensus rating of Wall Street analysts for Bristol-Myers Squibb Company is Moderate Buy (2.15), with a target price of $78.18, which is -2.25% compared to the current price. The earnings rating for Bristol-Myers Squibb Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bristol-Myers Squibb Company has a dividend yield of 2.93% with a dividend per share of $2.16 and a payout ratio of 273.00%.

Bristol-Myers Squibb Company has a Buy technical analysis rating based on Technical Indicators (ADX : 5.10, ATR14 : 1.50, CCI20 : 166.35, Chaikin Money Flow : 0.16, MACD : 0.23, Money Flow Index : 66.61, ROC : 3.09, RSI : 65.84, STOCH (14,3) : 99.45, STOCH RSI : 1.00, UO : 65.39, Williams %R : -0.55), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bristol-Myers Squibb Company in the last 12-months were: Adam Dubow (Sold 2 466 shares of value $167 441 ), Christopher S. Boerner (Option Excercise at a value of $0), Christopher S. Boerner (Sold 29 532 shares of value $2 043 525 ), David V. Elkins (Option Excercise at a value of $3 394 299), David V. Elkins (Sold 99 691 shares of value $6 674 497 ), Elizabeth A. Mily (Option Excercise at a value of $0), Giovanni Caforio (Option Excercise at a value of $0), Giovanni Caforio (Sold 150 000 shares of value $10 278 400 ), Julia A. Haller (Option Excercise at a value of $0), Karen Murphy Santiago (Option Excercise at a value of $0), Karen Murphy Santiago (Sold 6 577 shares of value $455 096 ), Paul von Autenried (Sold 76 134 shares of value $4 624 992 ), Powell Ann Judge (Option Excercise at a value of $0), Powell Ann Judge (Sold 23 280 shares of value $1 596 309 ), Rupert Vessey (Option Excercise at a value of $10 764 377), Rupert Vessey (Sold 232 952 shares of value $15 945 125 ), Samit Hirawat (Option Excercise at a value of $0), Sandra Leung (Option Excercise at a value of $0), Sandra Leung (Sold 94 390 shares of value $6 867 545 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (46.67 %)
6 (46.15 %)
6 (46.15 %)
Moderate Buy
0 (0.00 %)
1 (7.69 %)
1 (7.69 %)
Hold
7 (46.67 %)
5 (38.46 %)
6 (46.15 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (6.67 %)
1 (7.69 %)
0 (0.00 %)
Summary RatingModerate Buy
2.15
Moderate Buy
2.10
Moderate Buy
2.00

Bristol-Myers Squibb Company

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

CEO: Giovanni Caforio

Telephone: +1 212 546-4000

Address: 430 E. 29th Street, New York 10016, NY, US

Number of employees: 30 250

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

63%38%

Bearish Bullish

54%46%

Bearish Bullish

55%45%

TipRanks News for BMY

Mon, 16 May 2022 01:55 GMT Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Bristol Myers (BMY) and Kodiak Sciences (KOD)

- TipRanks. All rights reserved.

Mon, 02 May 2022 01:15 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Bristol Myers (BMY) and Eli Lilly & Co (LLY)

- TipRanks. All rights reserved.

Tue, 26 Apr 2022 01:57 GMT Berenberg Bank Believes Bristol Myers (BMY) Still Has Room to Grow

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 14:36 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Bristol Myers (BMY), Nabriva (NBRV) and Sanofi (OtherSNYNF)

- TipRanks. All rights reserved.

Tue, 01 Mar 2022 14:41 GMT Bristol-Myers: A Long-Term Dividend Growth Stock

- TipRanks. All rights reserved.

Wed, 16 Feb 2022 19:32 GMT Bristol-Myers Squibb: Deserves a Higher Valuation

- TipRanks. All rights reserved.

Wed, 16 Feb 2022 07:38 GMT Bristol Myers Squibb Updates 1 Key Risk Factor

- TipRanks. All rights reserved.

Thu, 10 Feb 2022 16:21 GMT Bristol-Myers Squibb: Positioned to Deliver

- TipRanks. All rights reserved.

Wed, 26 Jan 2022 18:37 GMT Bristol Myers: How Much Upside Is Left

- TipRanks. All rights reserved.

News

Stocktwits